References
- Lambert H, Gupte J, Fletcher H, et al. COVID-19 as a global challenge: towards an inclusive and sustainable future. Lancet Planet Health. 2020;4(8):e312–e314.
- McKee M, Stuckler D. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med. 2020;26(5):640–642.
- Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health. 2020;2(6):e286–e287.
- Callaway E. What Pfizer’s landmark COVID vaccine results mean for the pandemic. Nature. 2020. Epub ahead of print. DOI:10.1038/d41586-020-03166-8
- Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018;391(10130):1608–1621.
- Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184–210.
- Berry SA, Coughlin CR 2nd, McCandless S, et al. Developing interactions with industry in rare diseases: lessons learned and continuing challenges. Genet Med. 2020;22(1):219–226.
- Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol. 2017;13(6):327–339.
- Pance A. How elusive can a malaria vaccine be? Nat Rev Microbiol. 2019;17(3):129.
- Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med. 2020;8(1):19.
- World Health Organization. Global influenza strategy 2019–2030. World Health Organization; 2019. Available from: https://apps.who.int/iris/handle/10665/311184
- Luo GG, Gao SJ. Global health concerns stirred by emerging viral infections. J Med Virol. 2020;92(4):399–400.
- Morse SS, Mazet JA, Woolhouse M, et al. Prediction and prevention of the next pandemic zoonosis. Lancet. 2012;380(9857):1956–1965.
- Hamad M, Al-Marzooq F, Orive G, et al. Superbugs but no drugs: steps in averting a post-antibiotic era. Drug Discov Today. 2019;24(12):2225–2228.
- O’Neill J. Review on antimicrobial resistance antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
- IACG, U.I.C.G., No Time to Wait: securing the future from drug-resistant infections. 2019. Available from: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Davidson NE, Armstrong SA, Coussens LM, et al. AACR cancer progress report 2016. Clin Cancer Res. 2016;22(Suppl 19):S1–S137.
- Bright F, Werry EL, Dobson-Stone C, et al. Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15(9):540–555.
- 2020 Alzheimer’s disease facts and figures. Alzheimers Dement; 2020. p. 10.
- Moussa-Pacha NM, Abdin SM, Omar HA, et al. BACE1 inhibitors: current status and future directions in treating Alzheimer’s disease. Med Res Rev. 2020;40(1):339–384.
- Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–173.
- Zamora B, Maignen F, O’Neill P, et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019;14(1):95.
- Phuong JM, Penm J, Chaar B, et al. The impacts of medication shortages on patient outcomes: a scoping review. PLoS One. 2019;14(5):e0215837.
- Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016;2(9):1238–1240.
- Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533(7604):452–454.
- Yildirim O, Gottwald M, Schüler P, et al. Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. Front Pharmacol. 2016;7:461.
- Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–853.
- Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–164.
- Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opin Drug Discov. 2018;13(10):889–892.
- Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156.
- Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020;173(4):287–296.
- Pankevich DE, Altevogt BM, Dunlop J, et al. Improving and accelerating drug development for nervous system disorders. Neuron. 2014;84(3):546–553.
- Aronson JK, Green AR. Me-too pharmaceutical products: history, definitions, examples, and relevance to drug shortages and essential medicines lists. Br J Clin Pharmacol. 2020;86(11):2114–2122.
- Aronson JK, Ferner RE, Hughes DA. Defining rewardable innovation in drug therapy. Nat Rev Drug Discov. 2012;11(4):253–254.
- Pisano S, Pozzi M, Catone G, et al. Putative mechanisms of action and clinical use of lithium in children and adolescents: a critical review. Curr Neuropharmacol. 2019;17(4):318–341.
- Toussaint K, Yang XC, Zielinski MA, et al. What do we (not) know about how paracetamol (acetaminophen) works? J Clin Pharm Ther. 2010;35(6):617–638.
- Pratt J, Hall J. Biomarkers in neuropsychiatry: a prospect for the twenty-first century? Curr Top Behav Neurosci. 2018;40:3–10.
- Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–586.
- Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–1278.
- Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018;15(3):183–192.
- de Wilde S, Guchelaar HJ, Zandvliet ML, et al. Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol Ther Methods Clin Dev. 2016;3:16073.
- Quinn C, Young C, Thomas J, et al. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019;22(6):621–626.
- Seliger B. Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. Front Immunol. 2019;10:999.
- Golchin A. Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility. Stem Cell Rev Rep. 2020;1–7. https://doi.org/10.1007/s12015-020-10046-1
- Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356–361.
- Kaiser J. To streamline coronavirus vaccine and drug efforts, NIH and firms join forces. Science. 2020. doi:10.1126/science.abc3180